Hyoscyamine is an anticholinergic indicated to treat functional gastrointestinal disorders, biliary and renal colic, and acute rhinitis. Hyoscyamine is a tropane alkaloid and the levo-isomer of atropine.
- Mechanism
- Curator reviewed · 6 references
Hyoscyamine competitively and non-selectively antagonises muscarinic receptors in the smooth muscle, cardiac muscle, sino-atrial node, atrioventricular node, exocrine nodes, gastrointestinal tract, and respiratory tract. Antagonism of muscarinic M1, M4, and M5 receptors in the central nervous system lead to cognitive impairment; antagonism of M2 in the sinoatrial and atrioventricular nodes leads to increases in heart rate and atrial contractility; and antagonism of M3 in smooth muscle results in reduced peristalsis, bladder contraction, salivary secretions, gastric secretions, bronchial secretions, sweating, increased bronchodilation, mydriasis, and cycloplegia.
- Primary indication
- As a drug that is not FDA approved, hyscyamine has no official indications.Curator reviewed · 26 structured indications
- Formula / weight
- C17H23NO3 · 289.3694 g/mol (avg)
- First approval
- Canada, 1960
- Also known as
- (S)-atropine · Daturin · Daturine · Duboisine · L-Hyoscyamine
- Brand names
Resolves to
RKUNBYITZUJHSG-FXUDXRNXSA-NSMILESCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1What you can answer from here — as of September 27, 2026
Which drugs share a target with Hyoscyamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account